Elicio Therapeutics (9HA) AI Stock Analysis

0 Followers

Elicio Therapeutics

(Frankfurt:9HA)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

AMP Immunotherapy PlatformElicio’s lymph node-targeting AMP platform provides a defined technological approach across its cancer vaccine and immunotherapy pipeline. If clinical studies validate the intended immune response, the platform could support multiple oncology programs rather than relying on a single candidate.

Negative Factors

No Commercial RevenueElicio has not yet established meaningful commercial revenue, confirming that its business remains dependent on clinical development rather than product sales. Without an operating revenue base, future progress and corporate funding capacity remain tied to pipeline advancement and external capital.

Elicio Therapeutics (9HA) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 30.70M
Dividend Yield: ―
Average Volume (3M): 435
Price to Earnings (P/E): -0.9
Beta (1Y): -0.60
Revenue Growth: ―
EPS Growth: 49.89%
Country: Germany
Employees: 33
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Elicio Therapeutics Business Overview & Revenue Model

Company Description

Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP...

Elicio Therapeutics Risk Analysis

Elicio Therapeutics disclosed 93 risk factors in its most recent earnings report. Elicio Therapeutics reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

2 New Risks

1.Our planned Phase 1 study evaluating ELI-002 7P in combination with a RAS small molecule inhibitor with or without an anti-PD-1 inhibitor in metastatic mKRAS pancreatic cancer may present additional safety risks, and the combination of multiple agents may result in unexpected adverse events or tolerability issues.Q2, 2026

2.Our planned combination studies depend on the availability and cost of third-party therapeutic agents, including anti-PD-1 inhibitors and RAS small molecule inhibitors, and we may face challenges in securing adequate supply of such agents on acceptable terms.Q2, 2026

Elicio Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:9HA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CGEN	66Neutral	$197.98M	5.38	39.30%	―	999.97%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MIST	48Neutral	$82.44M	-0.96	-288.36%	―	―	21.42%
MCRB	37Underperform	$15.90M	-0.32	-148.34%	―	505.41%	-889.29%

* Healthcare Sector Average

Performance Comparison

DE:9HA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:9HA	Elicio Therapeutics, Inc	1.47	-6.38	-81.27%
CGEN	Compugen	2.09	0.41	24.40%
MCRB	Seres Therapeutics Inc.	1.56	-14.45	-90.26%
MIST	Milestone Pharmaceuticals	0.66	-1.27	-65.70%
ACTU	Actuate Therapeutics, Inc.	0.30	-6.00	-95.29%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Elicio Therapeutics AI Stock Analysis